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استعراف مبين على منظومة تغيريات ارقام النسخ لضبط التشخيص
حتليل كامل للجينوم باستخدام طريقيت الرتكيز اجليين والتميز املنخفض يف آن واحد
 رينات مرق�ض نيكل�صون، ايلني دوروتي، جنيفر م لوف، �صون �صينج لن، الي�ض م جورج، دونالد ر لوف،
انتوين ثرا�ض
بطريقتي  اجلينوم  كامل  بتحليل  ت�صمح  مقارن  جيني  تهجني  منظومة  �صحة  من  والتحقق  تطوير  اإىل  الدرا�صة  هدفت  الهدف:  امللخ�ص: 
 12x135 الأ�صتهداف لعدد من جينات املر�ض والتميز املنخف�ض يف اآن واحد. طرق الدرا�صة: مت ت�صميم منظومة بي�صبوك رو�ض نيمبلجني
ك للتهجني اجليني املقارن )�رسكة رو�ض نيمبلجني، مادي�صون، وينكون�صينو الوليات املتحدة الأمريكية( لتمحي�ض املناطق ال�صفرية يف 
66 جني مع ا�صتخدام م�صبارات اإ�صافية مت�صعة القاعدة من اأجل التغطية الكلية لكامل اجلينوم. مت حتليل احلام�ض النووي ثنائي الريبوز 
)د ن ا( من ع�رسين مري�صًا ذوي تغريات اأرقام ن�صخ �صابقة التعريف و ثمانية مر�صى مل يتم حتديد اجلرعة اجلينية لهم من قبل. النتائج: 
اي�صا بنجاح  الع�رسين. كما مت  الن�صخ يف كل املر�صى  ارقام  اأن حتدد تغريات  ا�صتطاعت منظومة رو�ض نيمبلجني تهجني جيني مقارن 
الت�صخي�ض اجلزيئي لأحد املر�صى الأربعة الذين مل يتم تاأكيد ت�صخي�صهم ال�رسيري بوا�صطة حتليل املتوالية من قبل. مت اأي�صا بنجاح حتديد 
حمل �صفة تغريات اأرقام الن�صخ للمر�صى الأربعة الباقني. اخلال�صة: منظومة رو�ض نيمبلجني تهجني جيني مقارن املو�صوفة يف هذا البحث 
هي طريقة دقيقة، �صامدة، وعالية املردود و مثالية لال�صتخدام يف املختربات الت�صخي�صية ال�صغرية. من املمكن ا�صتخدام هذة الطريقة 
كبديل للطرق الأخرى ال�صائعة ال�صتخدام مثل طريقة الربط املتعدد املعتمد علي ت�صخيم امل�صبار.
مفتاح الكلمات: منظومة تهجني جيني مقارن، جرعة جينية، متغريات اأرقام الن�صخ، ميكروارراي ال د ن ا، الت�صخي�ض اجلزيئي.
abstract: Objectives: The aim of this study was to develop and validate a comparative genomic hybridisation 
(CGH) array that would allow simultaneous targeted analysis of a panel of disease genes and low resolution whole 
genome analysis. Methods: A bespoke Roche NimbleGen 12x135K CGH array (Roche NimbleGen Inc., Madison, 
Wisconsin, USA) was designed to interrogate the coding regions of 66 genes of interest, with additional widely-
spaced backbone probes providing coverage across the whole genome. We analysed genomic deoxyribonucleic acid 
(DNA) from 20 patients with a range of previously characterised copy number changes and from 8 patients who 
had not previously undergone any form of dosage analysis. Results: The custom-designed Roche NimbleGen CGH 
array was able to detect known copy number changes in all 20 patients. A molecular diagnosis was also made for one 
of the additional 4 patients with a clinical diagnosis that had not been confirmed by sequence analysis, and carrier 
testing for familial copy number variants was successfully completed for the remaining four patients. Conclusion: 
The custom-designed CGH array described here is ideally suited for use in a small diagnostic laboratory. The 
method is robust, accurate, and cost-effective, and offers an ideal alternative to more conventional targeted assays 
such as multiplex ligation-dependent probe amplification.
Keywords: Array comparative genomic hybridization (aCGH); Gene dosage; Copy number variants (CNVs); DNA 
microarray; Molecular diagnosis.
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Advances in knowledge 
- Customised comparative genomic hybridisation (CGH) arrays, such as the one described here, allow robust high density gene-targeted 
as well as low density whole genome analysis to be undertaken simultaneously in the diagnostic setting. 
- Our data has shown that complicated gene rearrangements may underlie disease and that these rearrangements may be missed by 
more conventional diagnostic techniques.
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The importance of gene deletion and duplication in the pathogenesis of disease has become increasingly evident over the 
last decade. These deletions/duplications range 
from intragenic changes that are too large to be 
detected by sequence analysis, to larger genomic 
rearrangements responsible for the microdeletion 
and microduplication syndromes, and finally to 
whole chromosome loss or gain as seen in the 
aneuploidies.
In the discipline of cytogenetics, molecular 
karyotyping using high-density oligonucleotide 
arrays has recently become the recommended first-
line diagnostic test for patients with developmental 
delay/intellectual disability, autistic spectrum 
disorder, or multiple congenital anomalies, replacing 
more conventional techniques such as G-banded 
karyotyping.1,2 Large deletions and duplications 
have long been recognised as playing an important 
part in the pathogenesis of several disorders 
traditionally diagnosed using molecular techniques, 
such as Duchenne muscular dystrophy and Charcot-
Marie-Tooth disease type 1A.3,4 In addition to these 
classical deletion/duplication disorders, the role of 
partial or whole gene deletions in the aetiology of 
a wide variety of single-gene disorders is becoming 
more apparent. A 2008 review of the entries in the 
online Human Gene Mutation Database showed 
that large deletions and duplications comprise 10% 
of the listed mutations, compared to 6% in 2003.5,6 
This number is likely to increase further as more 
individuals are subjected to dosage analysis as part 
of routine molecular diagnostics. 
A variety of dosage analysis methods are 
available to the diagnostic laboratory, including 
multiplex ligation-dependent probe amplification 
(MLPA), quantitative real-time polymerase chain 
reaction (qPCR), and customised fluorescence in 
situ hybridisation (FISH).7–9 Each of these methods, 
however, is relatively expensive, principally as a 
result of the price of the probes, and in the case of 
MLPA and qPCR, is usually confined to a limited 
number of exons across a limited number of 
genes.10,11 Finally, in the case of a small diagnostic 
laboratory, low sample throughput decreases cost-
effectiveness, together with the attendant issue of 
maintaining staff proficiency in a range of dosage 
techniques.
In order to address the above difficulties, 
we designed a bespoke NimbleGen 12x135K 
comparative genomic hybridisation (CGH) array 
(Roche NimbleGen Inc., Madison, Wisconsin, 
USA). This array targets a panel of genes chosen 
to complement the sequencing assays offered 
in-house, as well as a number of other genes for 
which deletions and duplications are known to 
be implicated in a disease phenotype. In addition 
to this gene-focused coverage, the design of the 
array also involved low-density coverage of the 
entire human genome. Here, we report the use 
of this custom-designed array to analyse a series 
of 28 clinical samples in order to investigate the 
suitability of this approach for dosage analysis in the 
diagnostic environment.
Methods
A group of 20 individuals with a range of previously 
characterised copy number changes were selected 
for array comparative genomic hybridisation 
(aCGH) analysis. The patients, or parents in the 
case of neonates, provided informed consent 
for diagnostic testing; the New Zealand multi-
region ethics committee has ruled that cases 
of patient management do not require formal 
ethics committee approval. The copy number 
changes included both cytogenetic and molecular 
abnormalities, and spanned a spectrum from 
aneuploidy to intragenic deletion with three cases 
of aneuploidy, two of unbalanced translocations, 
three microdeletions, two microduplications, 
seven intragenic deletions, and three intragenic 
duplications. These changes had been identified 
using a range of techniques, including conventional 
and molecular karyotyping, FISH and MLPA [Table 
1]. aCGH was also completed for an additional 8 
individuals without known copy number changes 
for whom dosage analysis was desirable either for 
Applications to Patient Care
- The targeted CGH array with backbone format allows for diagnostic flexibility in a clinical laboratory setting.
- The added advantage of the approach described here is that it removes the need to batch the mutation screening of patients based on 
their clinical phenotype.
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diagnostic purposes or for completion of family 
studies. 
Peripheral blood ethylenediaminetetraacetic 
acid (EDTA) samples from each of these 28 
individuals were submitted to the Diagnostic 
Genetics Department at LabPLUS, Auckland City 
Hospital, New Zealand, for either molecular or 
cytogenetic analysis, as clinically indicated. 
Genomic diribonucleic acid (gDNA) was 
extracted from peripheral blood leucocytes 
using the Gentra Puregene DNA Extraction Kit 
(QIAGEN, Germantown, Maryland, USA). In 
those samples referred for conventional karyotype 
or FISH analysis, classical phenol/chloroform 
extraction with ethanol precipitation was used to 
isolate DNA from cultured leucocytes, in order to 
provide a source of gDNA for molecular testing.
A primer design protocol was used to design 
primers flanking the region spanning exons 11–14 
of the KCNH2 gene.12,13 In brief, the messenger RNA 
(mRNA) sequence of interest was identified using 
the University of California Santa Cruz (UCSC) 
genome browser.14 All primers were checked for 
single nucleotide polymorphisms using the software 
tool available from the National Genetic Reference 
Laboratory, Manchester, UK.15 The primers were 
tailed with M13 sequences and were synthesised 
by Invitrogen Ltd., Renfrewshire, UK (primer 
sequences are available on request).
Table 1: Copy number changes used to validate the Roche NimbleGen custom-designed comparative genomic 
hybridisation array
Patient Disorder/Copy Number Variants Description Previous testing method
1 Klinefelter syndrome XXY Karyotype
2 Down’s syndrome Trisomy 21 Karyotype
3 Edward's syndrome Trisomy 18 Karyotype




5 Unbalanced translocation t (3;4) 46,XX,der(4)t(3;4)(q23;q35.1)pat Karyotype
6 Microdeletion chr2 Del chr2:102176600-119933523 Illumina HumanCytoSNP 300K 
microarray
7 Autistic spectrum disorder Del chr2: 44305631-44425668; dup 
chr15: 36188779-36655207; del chr16: 
29522477-30107306
Affymetrix SNP 6.0 microarray
8 Prader-Willi syndrome Deletion of SNRPN gene Southern blot, FISH
9 Williams-Beuren duplication 
syndrome
Dup chr7: 71914639-73718403 Affymetrix SNP 6.0 microarray
10 Rett syndrome Duplication MECP2 gene MLPA
11 LQTS Del exons 6, 7,10,11,15 KCNH2 gene MLPA
12 LQTS Dup exons 10,11, 15 KCNH2 gene MLPA
13 Familial adenomatous polyposis Del exons 11-12 APC gene MLPA
14  DMD Del exon 45-52 DMD gene MLPA and multiplex PCR
15 DMD, carrier Dup exon 63 (heterozygous) DMD 
gene
MLPA
16 Familial breast cancer Del exon 1, 2 BRCA1 gene MLPA
17 DMD Del Ex3-44 DMD gene MLPA
18 HNPCC Del exon 6 MLH1 gene MLPA
19 Familial breast cancer Dup exon13 BRCA1 gene MLPA
20 Familial breast cancer Del exons 1,2 BRCA2 gene MLPA
FISH = fluorescence in situ hybridization; del chr = deleted chromosome; dup chr = duplicated chromosome; SNP = single nucleotide polymorphisms; 
LQTS = long QT syndrome; MLPA = multiplex ligation-dependent probe amplification; DMD = Duchenne muscular dystrophy;  PCR = polymerase 
chain reaction; HNPCC = hereditary non-polyposis colorectal cancer.
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Table 2: Human disease genes selected for inclusion on the Roche NimbleGen custom-designed comparative 
genomic hybridisation array









LQT KCNQ1 NM_000218.2 NP_000209 P51787 607542
KCNH2 NM_000238.2 NP_000229 Q12809 152427
SCN5A NM_198056.2 NP_932173 Q14524 600163
GPD1L NM_015141.2 NP_055956 Q8N335 611778
SCN1B NM_001037.4 NP_001028 Q07699 611778
NM_199037.3 NP_950238 Q6TN97 600235
SCN3B NM_018400.3 NP_060870 Q9NY72 608214
CACNB2 NM_201596.2 NP_963890 Q08289 600003
KCNE3 NM_005472.4 NP_005463 Q9Y6H6 604433
ANK2 NM_001148.3 NP_001139 Q01484 106410
KCNE1 NM_000219.3 NP_000210 P15382 176261
KCNE2 NM_172201.1 NP_751951 Q9Y6J6 603796
KCNJ2 NM_000891.2 NP_000882 P63252 600681
CACNA1c NM_001129827.1 NP_001123299 Q13936 114205
CAV3 NM_033337.1 NP_203123 P56539 601253
SCN4B NM_174934.3 NP_777594 Q8IWT1 608256
AKAP9 NM_005751.4 NP_005742 Q8IWT1 604001
HCM MYH7 NM_000257.2 NP_000248 P12883 160760
MYBPC3 NM_000256.3 NP_000247 Q14896 600958
TNNT2 NM_000364.2 NP_000355 P45379 191045
TNNI3 NM_000363.4 NP_000354 P19429 191044
TPM1 NM_001018020.1 NP_001018020 O15513 191010
ACTC1 NM_005159.4 NP_005150 P68032 102540
MYL2 NM_000432.3 NP_000423 P10916 160781
MYL3 NM_000258.2 NP_000249 P08590 160790
LAMP2 NM_001122606.1 NP_001116078 Q6Q3G8 309060
PRKAG2 NM_016203.3 NP_057287 Q9UGJ0 602743
GLA NM_000169.2 NP_000160 P06280 301500
CPVT RYR2 NM_001035.2 NP_001026  Q92736 180902
CASQ2 NM_001232.2 NP_001223 O14958 114251
ARVC DSP NM_004415.2 NP_004406 P15924 125647
PKP2 NM_001005242.2 NP_001005242 A0AV37 602861
DSG2 NM_001943.3 NP_001934 Q14126 125671
DSC2 NM_024422.3 NP_077740 Q02487 125645
JUP NM_002230.2 NP_002221 P14923 173325
TGFB3 NM_003239.2 NP_003230 P10600 190230
TMEM43 NM_024334.2 NP_077310 Q9BTV4 612048
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Polymerase chain reaction (PCR) amplification 
was performed in a total volume of 25 µL, containing 
50 ng of genomic deoxyribonucleic acid (DNA), 0.20 
µM of each primer, 1 mM of each dNTP, and 1.75 
U of expand long template enzyme mix in buffer 2 
(F. Hoffmann-La Roche Ltd., Basel, Switzerland). 
After an initial denaturation for 2 minutes at 94º 
C, the PCR amplification included 10 cycles of 94º 
C for 10 seconds, 60º C for 30 seconds, and 68º C 
for 2 minutes, followed by 20 cycles of 94º C for 15 
seconds, 60º C for 30 seconds, 68º C for 4 minutes, 
and a final extension at 68º C for 10 minutes. PCR 
products were separated by a 2% agarose gel and the 
lower band, corresponding to the allele carrying the 
DMD DMD NM_004006.2 NP_003997 P11532 300377
ALD ABCD1 NM_000033.2 NP_000024.2 P33897 300371
FAP APC NM_000038.3 NP_000029.2 P25054 611731
Type 1 citrullinaemia ASS1 NM_000050.4 NP_000041.2 P00966 603470
Type II citrullinaemia SLC25A13 NM_014251.2 NP_001153682.1 Q9UJS0 603859
Thyroid carcinoma/melanoma BRAF1 NM_004333.4 NP_004324.2 P15056 164757
Familial breast and ovarian cancer BRCA1 NM_007294.2 NP_009225.1 P38398 113705
BRCA2 NM_000059.3 NP_000050.2 P51587  600185
X-linked congential stationary night 
blindness type 2 
CACNA1F NM_005183.2 NP_005174.2 O60840 300110
E-cadherin related stomach cancer CDH1 NM_004360.2 NP_004351.1  P12830 192090
Larsen syndrome FLNB NM_001457.2 NP_001157789.1 O75369 603381
NKH GLDC NM_000170.2 NP_000161.2 P23378 238300
Holocarboxylase synthetase deficiency HLCS NM_000411.4 NP_000402.3 P50747 609018
MODY GCK NM_000162.3 NP_000153.1 P35557 138079
HNF1a NM_000545.4 NP_000536.5 P20823 142410
HNF1b NM_000458.2 NP_000449.1 P35680 189907
HNF4a NM_000457.3 NP_000448.3 P41235 600281
Familial hypercholesterolemia LDLR NM_000527.3 NP_000518.1 P01130 606945
Rett syndrome MECP2 NM_004992.3 NP_001104262.1 P51608 300005
HNPCC MLH1 NM_000249.2 NP_000240.1 P40692 120436
MSH2 NM_000251.1 NP_000242.1 P43246 609309
PMS1 NM_000534.4 NP_000525.1 P54277 600258
PMS2 NM_000535.5 NP_000526.1  P54278 600259
MEN2A RET NM_020630.4 NP_065681.1 P07949 64761
Familial phaeochromocytoma/ 
paraganglioma
SDHAF2 NM_017841.1 NP_060311.1  Q9NX18 613019
SDHB NM_003000.2 NP_002991.2  P21912 185470
SDHC NM_003001.3 NP_001030588.1 Q99643 602413
SDHD NM_003002.1 NP_002993.1 O14521 602690
DYT11 SGCE NM_003919.2 NP_001092870.1  O43556 604149
VHL VHL NM_000551.2 NP_000542.1  P40337  608537
LQT = long QT syndrome; HCM = hypertrophic cardiomyopathy; CPVT = catecholaminergic polymorphic ventricular tachycardia; ARVC 
= arrhythmogenic right ventricular cardiomyopathy; DMD = Duchenne muscular dystrophy; ALD = adrenoleukodystrophy; FAP = familial 
adenomatous polyposis; NKH = nonketotic hyperglycinemia; MODY = maturity onset diabetes of the young: HNPCC = hereditary non-polyposis 
colorectal cancer; MEN2A = multiple endocrine neoplasia type 2A; DYT11 = Myoclonus dystonia; VHL = Von-Hippel Lindau syndrome. 
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deletion, was excised and purified using the Roche 
High Pure PCR Cleanup Micro Kit (Roche Applied 
Sciences, Roche Diagnostics, Penzberg, Germany). 
Bidirectional DNA sequencing was performed 
using M13 forward and reverse primers and Big-
Dye Terminator, Version 3.0 (Applied Biosystems 
Ltd., Carlsbad, California, USA). Using an 
automated Clean-Seq procedure (Agencourt 
Bioscience Corp., Beverly, Massachusetts, USA), 
20 µL of sequenced product was purified with 
the aid of an epMOTION 5075 liquid handling 
robot (Eppendorf, Hamburg, Germany). Using the 
Applied Biosystems model 3130xl genetic analyser 
(Applied Biosystems, Inc., Foster City, California 
USA), 15 µL of purified product was then subjected 
to capillary electrophoresis. 
Genes of interest, including those already 
sequenced in-house and those pertaining to 
common disorders known to frequently involve 
deletions/duplications (such as Duchenne muscular 
dystophy), were selected and the appropriate NM 
accession numbers identified using the UCSC 
genome browser. The final gene list comprising 
66 genes was forwarded to NimbleGen and 
formed the basis of their design for a 12-plex 135K 
oligonucleotide array (see Table 2 for gene list). Each 
probe was 60–85 bp in length and possessed similar 
isothermal characteristics. Exonic probes were 
designed to overlap by 25 bp in order to provide high 
resolution detection of deletions or duplications 
within the coding regions of the genes of interest. 
Intronic probes were spaced on average every 175 
bp. To minimise the occurrence of false positive 
results due to a one-off failure of hybridisation to 
a particular probe, each gene-focused probe was 
spotted in duplicate. In addition to the targeted 
probes tiled over the genes of interest, approximately 
75,000 ‘backbone’ probes were also included. These 
probes were spaced across the entire genome (with 
a mean probe interval of 46 kbp) to provide low-
density whole genome interrogation, as well as 
increase the accuracy of data normalisation during 
the analysis procedure. Following completion of 
the design process, the array was manufactured by 
NimbleGen, Inc.
A total of 250 nanograms of genomic 
deoxyribonucleic acid (gDNA) were processed 
according to the NimbleGen Array User’s Guide: 
CGH and CNV Arrays, Version 6.0. In brief, 
extracted gDNA from samples and Promega 
controls was denatured in the presence of a Cy3- 
for the test group or Cy5- for the control group, 
labelled random primers and incubated with the 
Klenow fragment of DNA polymerase, together 
with deoxyribonucleotide triphosphates (dNTPs) 
(5 mM of each dNTP), at 37º C for 2 hours. The 
reaction was terminated by the addition of 0.5 M 
EDTA (21.5 µL), prior to isopropanol precipitation 
and ethanol washing. Following quantification, 
the test and sex-matched control samples were 
combined in equimolar amounts and applied to 
one of the twelve arrays on the microarray slide. 
Hybridisation was carried out in a NimbleGen 
Hybridisation Chamber for a period of 48 hours. 
Slides were washed and scanned using a NimbleGen 
MS 200 microarray scanner. Array image files (.tif ) 
produced by the MS 200 Data Collection Software 
were imported into NimbleScan Version 2.6 for 
analysis. Each genomic region exhibiting a copy 
number change within one of the genes of interest 
was examined using the UCSC genome browser 
to determine the location and significance of the 
change. Data was filtered using the default log2 ratio 
thresholds recommended in the NimbleGen Array 
User’s Guide of less than -0.2 for a deletion and 
greater than 0.2 for duplication. 
For MLPA, the SALSA MLPA P114 LQT kit 
(lot 0805) was purchased from MRC-Holland 
(Amsterdam, Netherlands). This mix contains 
probes for 17 exons of the KCNQ1 gene, 9 probes 
for the KCNH2 gene, 4 probes for the SCN5A gene, 
as well as 4 and 3 probes for KCNE1 and KCNE2, 
respectively. This kit also contains four control 
probes mapping to other autosomes. MLPA analysis 
was carried out according to the MRC Holland 
protocol. Briefly, 125 ng of genomic DNA from each 
sample was diluted in 5 µl TE buffer and denatured 
at 98º C for 5 minutes. MLPA buffer and probe mix 
(1.5 µl of each) were then added to allow the probes 
to anneal to their target sequences by heating at 
95º C for one minute and incubating for 16 hours at 
60º C. A buffer/ligase mixture (32 µl) was added to 
each sample and incubated at 54º C for 15 minutes 
followed by heating to 98º C for 5 minutes. Ten 
microlitres of the ligation reaction were used for 
multiplex PCR amplification using a single universal 
primer pair suitable for all the probes in the kit. The 
SALSA polymerase was added at 60º C, followed 
by 36 cycles of 95º C for 30 seconds, 60º C for 30 
seconds, 72º C for one minute, and a final extension 
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Table 3: Custom- designed CGH array results for all samples
Patient Previous result Custom array raw result Significance of result
1 XXY arr Xp22.33q28(6,329-154,894,377)x3 XXY
2 Trisomy 21 arr 21q11.2q22.3(9,931,865-46,914,745)x3 Trisomy 21





t(7;22), coordinates consistent 
with previous result
5 46,XX,der(4)t(3;4)(q23;q35.1)pat arr  4q34.3q35.2(182,454,628-191,220,565)
x1,3q23q29(144,114,087-199,377,478)x3
t(3;4), coordinates consistent 
with previous result
6 Del chr2:102176600-119933523 arr 2q12.1q14.2(102,195,252-119,812,387)
x1
Del chr2, coordinates consistent 
with previous result
7 Del chr2: 44305631-44425668; dup chr15: 





Multiple CNVs, coordinates 
consistent with previous result
8 Deletion of SNRPN gene arr 15q11.2q13.1(21,450,428-26,192,737)
x1
Del entire SNRPN gene
9 Dup chr7: 71914639-73718403 arr 7q11.23(71,964,201-73,874,826)x3 Dup chr7, coordinates consistent 
with previous result
10 Dup MECP2 gene arr Xq28(152,900,329-153,202,330)x3 Dup entire MECP2 gene
11 Del exons 6, 7,10,11,15 KCNH2 gene arr 7q36.1(150,250,593-150,283,627)x1 Del exons 6-15 (inclusive)
12 Dup exons 10,11, 15 KCNH2 gene arr 7q36.1(150,250,593-
150,275,172x3,150,275,345-
150,276,020x1,150,276,456-150,279,665x3)
Dup exons 7,8,9,10,11; del exons 
12,13; dup exons 14,15
13 Del exons 11-12 APC gene arr 5q22.2(112,190,700-112,191,901)x1 Del exons 11,12
14 Del exon 45-52 DMD gene arr Xp21.1(31,625,116-31,904,144)x0 Del exons 45-52 (inclusive)
15 Dup exon 63 (heterozygous) DMD gene arr Xp21.2(31,155,081-31,194,353)x3 Dup exon 63 (heterozygous)
16 Del exon 1, 2 BRCA1 gene arr 17q21.31(38,525,107-38,531,019)x1 Del exons 1,2
17 Del Ex3-44 DMD gene arr Xp21.2p21.1(31,048,707-32,916,496)x0 Del exons 3-44 (inclusive)
18 Del exon 6 MLH1 gene arr 3p22.2(37,025,008-37,027,636)x1 Del exon 6
19 Dup exon13 BRCA1 gene arr 17q21.31(38,484,216-38,488,483)x3 Dup exon 13
20 Del exons 1,2 BRCA2 gene arr 13q13.1(31,787,734-31,788,803)x1 Del exons 1,2
Individuals with no known copy number change
Referral reason Custom array raw result Significance of result
21 Mother of patient 9 No CNV detected De novo dup chr7 in patient 9
22 Father of patient 9 No CNV detected De novo dup chr7 in patient 9
23 Mother of patient 7 arr 15q14(36,188,779-36,655,207)x3 Carrier of chr15 dup; de novo 
deletion chr16 in patient 7
24 Father of patient 7 arr 2p21(44,325,958-44,373,442)x1 Carrier of chr2 del; de novo 
deletion chr16 in patient 7
25 LQTS No CNV detected Pathogenic mutation not 
detected
26 LQTS No CNV detected Pathogenic mutation not 
detected
27 MODY No CNV detected Pathogenic mutation not 
detected
28 HNPCC arr 2p21(47,486,274-47,559,311)x1 Del exons 2-14 MSH2 gene
del chr = deleted chromosome; dup chr = duplicated chromosome; LQTS = long QT syndrome; MODY = maturity onset diabetes of the young; 
HNPCC = hereditary non-polyposis colorectal cancer.
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step of 72º C for 20 minutes. One microlitre of each 
PCR product was mixed with 0.5 µl GeneScan 600 
Liz size standard (Applied Biosystems, Ltd.) and 
8.5 µl of deionized formamide and 1µl was injected 
into a 36 cm capillary (Applied Biosystems model 
3130XL)) at 60º C. The electropherogram was 
analysed using GeneMapper software (Applied 
Biosystems Ltd.). For each sample, the relative 
peak area (RPA) was calculated and compared to 5 
healthy controls using custom-designed software. 
The software calculates RPAs for each probe within 
the same test and compares each RPA to those 
obtained from the 5 controls.
Results
We developed a custom-designed NimbleGen 
12x135K aCGH that combines targeted high-
density coverage of 66 genes of interest with 
genome-wide coverage to produce a low-resolution 
molecular karyotype. For the validation of this array 
we analysed 20 patients with known copy number 
abnormalities. The custom designed NimbleGen 
CGH array was able to accurately identify 
these copy number changes in all 20 patients 
[Table 3].
The array results for patient 12 revealed an 
additional alteration that had not been recognised 
previously. Patient 12 is a member of a large pedigree 
with multiple members suffering from long QT 
syndrome (LQTS). Analysis using the MRC-Holland 
SALSA P114 LQT MLPA kit, which interrogates a 
limited number of exons of the KCNH2 gene (exons 
1-4,6,7,10,11,15), had identified a duplication of 
exons 10, 11, and 15 in all affected individuals 
[Figure 1, panel A].16 This duplication had therefore 
been the focus of predictive testing using MLPA for 
additional at-risk members of the family. The aCGH 
results clarified the extent of the duplication, not 
only showing that it involved a breakpoint within 
exon 7 and encompassed the whole of exons 8, 9, 
10, 11, 14 and 15, but also that the genotype was 
more complex than previously thought. A critical 
micro-deletion encompassing exons 12 and 13 was 
Figure 1: Graphic representation of copy number changes in the KCNH2 gene in patient 12. (A) Dosage changes were 
detected using a multiplex ligation-dependent probe amplification (MLPA) approach. The graphic representation 
shows the increased dosage detected by probes that lie in exons 10, 11, and 15 of the KCNH2 gene. (B) Dosage changes 
were detected in the KCNH2 gene with a copy number gain (X3 copy number) defined by the chromosome 7 
coordinates (NCBI36/hg18 assembly) 150,276,456-150,279,665bp (within exon 7 to within exon 11, log2 ratio 0.45) and 
150,250,593-150,275,172 (encompassing exons 14 and 15, log2ratio 0.5), and an apparent 676bp deletion (X1 copy 
number, log2ratio -0.53) located at 150,275,345-150,276,020bp (encompassing exons 12 and 13). (C) Transcripts 
expressed from the KCNH2 gene are shown, together with the distal exons of transcript 1 of the KCNH2 gene (RefSeq 
accession number NM_000238.3).
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detected [Figure 1, panels B and C]. PCR and DNA 
sequencing determined the exact breakpoints of 
the 1041 bp deletion, the length of which compares 
favourably to the 676 bp copy number change 
detected by the array [Figure 2].
Of the 8 patients who had not yet undergone 
any form of copy number analysis, 4 had a clinical 
diagnosis that had not been confirmed by sequence 
analysis of the implicated genes: two had a diagnosis 
of long QT syndrome, one of hereditary non-
polyposis colorectal cancer (HNPCC), and one of 
maturity onset diabetes of the young (MODY). No 
copy number changes were identified in the panel 
of long QT syndrome genes in either of the long 
QT patients, nor within the MODY genes in the 
MODY patient. However, a large deletion involving 
exons 2–14 inclusive of the MSH2 gene was 
detected in the individual with a clinical diagnosis 
of hereditary non-polyposis colorectal cancer 
(HNPCC). Mutations in the mismatch repair gene 
MSH2 are known to be responsible for 40% of cases 
of HNPCC; 20% of these mutations involve exonic 
or full gene deletions.17
The referral reason for aCGH analysis for 
the remaining 4 individuals without a known 
copy number change was to provide additional 
information for genetic counselling and family 
planning. Individuals 21 and 22 are the parents 
of patient 9, an eight-year-old girl with mild 
dysmorphic features and speech delay, who had 
been found to have a duplication involving the 
Williams-Beuren syndrome (WBS) critical region 
at 7q1123 using an Affymetrix single nucleotide 
polymorphisms (SNP) 6.0 array (Affymetrix, Santa 
Clara, California, USA). While a microdeletion of the 
WBS critical region results in a well-characterised 
pattern of facial dysmorphism, supravalvular 
aortic stenosis, connective tissue abnormalities, 
hypercalcaemia, and a recognisable behavioural 
phenotype, duplication of the same region results 
in a much less distinctive set of characteristics.18 
Foremost among these, as was seen in our 
patient, are mildly dysmorphic facial features and 
prominent speech delay. Parental transmission 
of the 7q11.23 duplication is relatively frequent 
in the WBS duplication syndrome, but reduced 
penetrance and variable expression mean that 
determination of carrier status based on phenotype 
alone is not simple. An approximately 1.5 Mb 
duplication of the WBS critical region was readily 
indentified in the affected girl by our custom-
designed NimbleGen CGH array, which agreed 
with the earlier Affymetrix SNP 6.0 array data, 
but was not detected in either of her parents. 
Figure 2: Location and extent of the KCNH2 gene deletion in patient 12. A partial sequence of the KCNH2 gene is 
shown that encompasses exons 11 to 13, inclusive (in blue). The sequence-confirmed location and extent of the 1041bp 
deletion detected in the genome of patient 12 is highlighted in yellow (chromosome 7: 150,276,375-150,275,335bp; 
NCBI36/hg18 assembly).
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The conclusion is that the genomic copy number 
change detected in patient 9 is a de novo event and 
that future pregnancies are not at high risk of this 
mutation event.
Individuals 23 and 24 are the parents of 
patient 7, a six-year-old boy who was referred for 
investigation of developmental delay and features 
consistent with  autistic spectrum disorder. High-
density Affymetrix SNP 6.0 microarray analysis 
had revealed several copy number changes in 
the child, including a deletion at chromosome 
2p21, a duplication at chromosome 15q14, and a 
deletion at chromosome 16p11.2 (see Table 3 for 
full coordinates). Each of these changes was also 
identified by our NimbleGen custom CGH array, 
with only minor differences in breakpoint location, 
despite the difference in probe density [Table 3]. The 
16p11.2 deletion is consistent with the phenotypic 
features in this case, as dosage changes at 16p11.2 
have been described in association with autistic 
spectrum disorder.19 The aCGH results confirmed 
that the chromosome 16p11.2 deletion is de novo 
and that each of the other two copy number changes 
are most likely to be benign, as each is inherited 
from one of his parents.
Discussion
The purpose of the work described above was 
to design and validate a CGH array that could be 
used as an alternative to MLPA, quantitative PCR, 
and customised FISH in the diagnostic genetics 
laboratory. Although there have been several 
reports in the recent literature of custom-designed 
CGH arrays being used to screen for either exonic 
dosage changes in a large set of disease-specific 
genes, or for one of a panel of known genomic 
disorders, this is the first report, to our knowledge, 
of a custom-designed CGH array that provides 
both high-resolution coverage of a comprehensive 
set of genes and low-resolution whole genome 
coverage.20-25
The array design we report here is ideally suited 
to a small diagnostic laboratory. It enables the 
simultaneous interrogation of a large number of 
genes using a process that eliminates the risk of 
false negatives inherent in PCR-based techniques 
due to the possibility of polymorphisms lying under 
primer binding sites. Twelve patient samples are 
able to be tested at once, reducing the overall cost of 
the assay. The overlapping probes tile the exons at a 
high density and allow changes involving the coding 
regions of the gene(s) of interest, including single 
exon changes, to be readily and reliably detected. 
This design feature is in contrast to some previously 
reported designs which could not reliably detect 
single exon changes due to insufficient probe 
coverage over affected regions.23 The intron probes 
enable clarification of breakpoints, which is not 
possible with MLPA or qPCR, and the backbone 
probes facilitate the identification of larger genomic 
rearrangements, either as confirmation following 
high-density molecular karyotyping, or for carrier 
testing and family studies.
Conclusion
We have shown that our custom-designed 
NimbleGen CGH array can be used to accurately 
identify exonic deletions and duplications in a gene 
set of interest as well as offer a low resolution whole 
genome screen for larger genomic rearrangements. 
The technique is robust and cost-effective and 
allows for comprehensive analysis. This approach 
overcomes the problems associated with the use 
of expensive kits in the context of low sample 
throughput, and allows for consolidation of dosage 
analysis assays to a single validated technique.
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